Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05773859
PHASE1/PHASE2

NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer

Sponsor: Radboud University Medical Center

View on ClinicalTrials.gov

Summary

This goal of this single arm, single center, exploratory phase I/II clinical trial is to learn more about the immunological efficacy, safety and feasibility of an autologous tumor lysate-loaded autologous XP-DC (cDC1)-based vaccine in patients with ovarian cancer.

Official title: Induction of Neo-Antigen Specific Cytotoxic T Cells by Autologous Tumor Lysate-loaded Specialized Cross-Presenting Dendritic Cells in Epithelial Ovarian Cancer Patients Treated With Neoadjuvant Chemotherapy, the NEODOC Study

Key Details

Gender

FEMALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2023-03-17

Completion Date

2026-12-31

Last Updated

2025-11-18

Healthy Volunteers

No

Interventions

BIOLOGICAL

XP-DC vaccinations

Autologous cross-presenting dendritic cells loaded with autologous tumor lysate and KLH

Locations (1)

Radboud University Medical Center

Nijmegen, Gelderland, Netherlands